THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION. (12th June 2019) - Tarantelli, C.; Spriano, F.; Golino, G.; Gaudio, E.; Scalise, L.; Cascione, L.; Zucca, E.; van Berkel, P.; Stathis, A.; Zammarchi, F.; Bertoni, F.